anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Central venous catheters are an essential part of patient management in the ICU (Intensive Care Unit). The use of these catheters is associated with infectious complications that are an important iatrogenic source of morbidity and mortality. Many catheters become colonized with bacteria but only a proportion of colonised catheters go on to cause bacteriemia and sepsis. It is currently impossible to prospectively identify which of the catheters will become colonized and lead to sepsis. Various types of antiseptic or antimicrobial vascular catheter coatings have been developed. Studies showed that the coated catheters were effective in limiting the catheter colonization rate and that they may decrease the risk of catheter-related bloodstream infections. The "Certofix protect" was developed by B.Braun to reduce the risk of catheter related infections. It is a catheter with a modified surface that consists of a high molecular weight polymer which is non-covalently linked to the polyurethane catheter material. This clinical trial is performed to compare the safety and efficacy of the coated central venous catheter, Certofix® protect, with that of the non-coated standard catheter Certofix®.
About 80% of patients develop high glucose after cardiac surgery. High glucose is linked to an increased risk of hospital complications. High glucose increases the risk of wound infection, kidney failure and death. Patients with high glucose are treated with insulin given through an arm vein or by frequent insulin injections under the skin. This study will determine if sitagliptin can prevent the development of high glucose after heart surgery. Sitagliptin is a diabetes pill approved by the Food and Drug Administration (FDA) to treat patients with diabetes.
The present invention relates to a transparent gel cosmetic composition. The transparent gel cosmetic composition according to the present invention, which is a gel phase that can be obtained through gelation, has excellent formulation stability by including natural gum and having high viscosity characteristics, and also is applicable to the skin and can be absorbed by the skin, and thus can achieve a superb moisturizing effect. The transparent gel cosmetic composition according to the present invention is a highly viscous gel phase, and thus has excellent applicability and a fast absorption rate. Consequently, a phenomenon in which a cosmetic composition is pushed off the skin is significantly reduced. Moreover, a production method is simple and economical, and the transparent gel cosmetic composition has an appearance similar to grains of ice, thus having an aesthetically differentiating effect compared to typical smooth transparent gels. In addition, by containing natural gum, the transparent gel cosmetic composition has an excellent moisturized sensation transferring effect, and thus has an excellent effect of temporarily reducing skin temperature.
PURPOSE:To obtain a nitrogen-containing polysaccharide showing antitumor activity, having low toxicity from a culture, by cultivating a new strain belonging to the genus Pseudomonas in a medium comprising seawater, artificial seawater, etc. as a substrate under aerobic conditions. CONSTITUTION:The above-mentioned strain, namely, Pseudomonas sp.2319 is cultivated in a medium comprising seawater, artificial seawater, or 3wt% saline solution as a substrate blended with an N source such as peptone, meat extract, etc. under aerobic conditions to give the desired nitrogen-containing polysaccharide(M-2319). The cultivation is carried out with keeping the pH of the medium approximately at neutrality at 25-27 deg.C, a mold is removed from the culture by centrifugation, the above-mentioned M-2319 is obtained by separation from the filtrate and purification. This substance shows no clear melting point, decomposes approximately at 300 deg.C, changes into brown, has specific molecular weight, solubility, color reaction, specific rotatory power, infrared absorption, and constituent saccharide of carbohydrate part, and constitution of amino acid is alanine.
PURPOSE:To provide the subject new compound exhibiting strong kinetic cell death suppressing action without accompanying cardiac inhibitory action and useful as a preventive and treating agent for acute myocardial infarction. CONSTITUTION:The objective compound is expressed by formula I (R is H or 1-3C alkoxy; X is O or H2; n is 1 or 2; R<1> is phenyl substituted with OH, etc., or H, etc.; Ph is phenyl) or its salt, e.g. 4-acryloyl-2,3,4,5-tetrahydro-1,4- benzothiazepine. The compound can be produced e.g. by reacting a compound of formula II with acryloyl chloride of formula III in an aprotic solvent (e.g. THF) in the presence of a base (e.g. triethylamine) at 0 deg.C to room temperature and reacting the resultant amide compound of formula IV with 4- benzylpiperidine of formula V in a solvent (e.g. THF) at room temperature.
With obesity at an all-time high, understanding eating behavior beyond physical need is a priority. Food reinforcement is driven by central dopamine activity. However, objective measurement of brain dopamine-related behavioral events is hindered by the lack of non-invasive, accessible techniques that are amenable to testing in a "naturalistic" environment. The goal of this project is to develop a non-invasive, accessible methodology to measure dopaminergic responses to food in a natural setting. This research will use a novel, hand-held electroretinograph (ERG) that does not require eye dilation and uses a skin electrode to measure retinal dopamine activity. Previous work establishes that retinal dopamine activity can be used as a proxy for central dopamine function. The ability to assess both subjective behavioral variables and central dopaminergic responses simultaneously will provide an ideal approach for innovative studies of the control of eating behavior.
After the first week of e-cigarette use (JUUL), participants will be given placebo bupropion with placebo zonisamide. The combination of these placebos will continue for 7 weeks of treatment, and e-cigarette use will continue until the end of the study (an additional 4 weeks).
Asthma is the most common chronic illness of childhood. Bilevel positive airway pressure (BPAP) has been suggested as an adjunct therapy in the setting of moderate to severe asthma exacerbations. It is a form of noninvasive positive pressure ventilation that provides both an inspiratory positive airway pressure (IPAP) as well as an expiratory positive airway pressure (EPAP).

The goal of this study is to determine the feasibility of enrolling, randomizing, and completing data collection in at least 30 participants over a one-year period. The investigators will enroll children 5 to 17 years of age presenting to the emergency department with a moderate to severe asthma exacerbation. Eligible participants will be randomized into two groups: standard therapy (continuous albuterol) or standard therapy plus BPAP. The following data will be collected: Pediatric Respiratory Assessment Measure (PRAM) score at 0, 2 and 4 hours, vital signs at 0, 2 and 4 hours, rate of adverse events and Pediatric Intensive Care Unit (PICU) admissions, duration continuous albuterol, length of hospital stay, and rates of intubations or deaths.
The reproduction and ability to cause root-galling of a California isolate of the peach root-knot nematode Meloidogyne floridensis was evaluated on seven sweetpotato (Ipomea batatas) cultivars and compared with an M. incognita race 3 and an M. incognita Mi-gene resistance-breaking isolate. The susceptible tomato (Solanum lycopersicum) cultivar Daniela and the Mi-gene-carrying resistant cultivar Celebrity were included as controls. Repeated trials were done in pots in a nematode-quarantine greenhouse at the University of California, Riverside. The three Meloidogyne isolates reproduced equally well on susceptible tomato. On Mi-gene resistant tomato, the reproduction and root-galling by M. floridensis was intermediate between the avirulent M. incognita race 3 and the resistance-breaking M. incognita isolate. The sweetpotato cultivars 'Beauregard' and 'Diane' were excellent hosts for all three Meloidogyne isolates. Cultivars Bellevue, Burgundy, and Covington were resistant to these isolates. The cultivars Bonita and Murasaki-29 were hosts for the M. floridensis and the resistance-breaking M. incognita isolate, which allowed an increase in nematode levels, but they were poor hosts, resulting in a decrease in nematode levels for the M. incognita race 3 isolate. The study showed that M. floridensis can reproduce on tomato and some sweetpotato cultivars that are considered resistant to M. incognita.
PROBLEM TO BE SOLVED: To provide a method and an apparatus for treating mammals to achieve a desired topical or systemic and physiological or pharmacological effect. SOLUTION: The method comprises the steps of administering, to a mammal in need of above treatment, a sustained-release drug delivery system in a region where release of an effective agent is necessary, and allowing the effective agent to pass through the apparatus in a controlled manner. The apparatus (1) comprises an inner core or a reservoir (5) to contain the effective agent; a first coating layer (10) which has essentially no permeability toward the passing of the effective agent; and a second coating layer (15) which has a permeability toward the passing of the effective agent. The first coating layer covers at least a part of the inner core. But at least a small part of the inner core is not covered with the first coating layer. The second coating layer covers essentially all of the first coating layer and the uncovered region of the inner core.
Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent. Subjects will be treated with paclitaxel for at least 6 months, and may continue on paclitaxel at the discretion of the Investigator, or discontinued sooner if the subject has disease progression, an unacceptable toxicity or withdraws consent.
DS-01 is a rationally defined microbial consortia consisting of 24 strains across 12 species, with polyphenolic and phenolic prebiotic bioactive compounds. Participants will be instructed to take 2 capsules daily for the duration of the trial.
Described herein are methods for preparing a fibrin matrix comprising a fusion peptide. In some embodiments, the method comprises providing three different components, including a first component comprising fibrinogen or a fibrinogen precursor and optionally transglutaminase or a transglutaminase precursor, a second component comprising thrombin or a thrombin precursor, and a third component comprising a fusion peptide. In these embodiments, neither the first component nor the second component comprises a fusion peptide. In some embodiments, the first or second component is premixed with the third component. The first, second and third components are mixed to form a fibrin matrix comprising covalently linked fusion peptides. The mixing is carried out over a time period not exceeding 5 days. Also described herein are kits for preparing a fibrin matrix comprising covalently linked fusion peptides.
RISPERDAL CONSTA may induce orthostatic hypotension associated with dizziness, tachycardia, and in some patients, syncope, especially during the initial dose-titration period with oral risperidone, probably reflecting its alpha-adrenergic antagonistic properties. Syncope was reported in 0.8% (12/1499 patients) of patients treated with RISPERDAL CONSTA in multiple-dose studies. Patients should be instructed in nonpharmacologic interventions that help to reduce the occurrence of orthostatic hypotension (e.g., sitting on the edge of the bed for several minutes before attempting to stand in the morning and slowly rising from a seated position).

RISPERDAL CONSTA should be used with particular caution in (1) patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension, e.g., dehydration and hypovolemia, and (2) in the elderly and patients with renal or hepatic impairment. Monitoring of orthostatic vital signs should be considered in all such patients, and a dose reduction should be considered if hypotension occurs. Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication.
INTRODUCTION: Adoption of robotic liver resections has been gradually increasing throughout the HPB surgical community over the past decade. Currently there is limited literature which demonstrates a significant benefit of robotic surgery for major hepatectomies over open or laparoscopic. As one of the first centers to develop a robotic HPB program, we have experienced improved outcomes over time with increasing utilization of robotics. Herein, we present our 10-year experience and outcomes for major robotic liver resections.
METHODS: From 2012 to 2022, 361 robotic liver procedures were performed, including 100 major hepatectomies. A retrospective data review of the electronic medical record was performed evaluating outcomes after robotic major hepatectomy. Outcomes for the first 50 cases (Group A) and second 50 cases (Group B) were compared to identify any improvements in practice. Demographic and clinical outcome variables were analyzed. Data were assessed for normality, and Wilcoxon rank-sum, χ2 tests, and a logistic regression model were performed appropriate for the data. Stata v.17 was utilized, and significance was set as p < .05.
RESULTS: There was no difference in median operative time (258 vs 256 min), EBL (500 vs 500 mL), median LOS (5 vs 3.5 days), 90-day readmission (14% vs 24%), major complications (14% vs 20%), and 90-day mortality (6% vs 4%) between early and late cases, respectively. ICU admissions and conversion rates were significantly lower in group B (14.0% vs 48.0%), while expert level difficulty indices were higher (82% vs 58%).
CONCLUSION: Development of a robotic liver program with good outcomes is feasible over time. Our data suggest that our institutional learning curve for robotic major hepatectomy plateaued at approximately 50 cases.
FIELD: biotechnology. SUBSTANCE: method involves ultrafiltration and dialysis of immunoglobulin semifinished product followed by the temperature treatment at 30-58 C for 2 h, not less, or for 45 days, not above. At all stages of technological process the resistance value of immunoglobulin solution is maintained at the level 0.1 MOhm x cm, not less. Method ensures to obtain the preparation of immunoglobulin for intravenous use at value AKA 10 and more mg/2CH50 and no containing aggregates. EFFECT: improved method of producing. 3 tbl, 3 ex
Thulium fiber laser enucleation of the prostate (ThuFLEP) has already shown the outcomes comparable to OSP with better safety profile (lower blood loss compared to OSP) and shorter hospital stay. TFL has the efficacy and safety proven in comparative trials, being a promising rival for HoLEP. The main features of TFL distinguishing it from Ho:YAG is its wavelength of 1.94 µm (leading to about three-fold increase in water absorption and lesser penetration depth of \<0.1 mm vs \>0.2 mm in Ho:YAG). With identical average and peak powers of 100 W, the laser does not burst tissues, allowing for clean and precise cutting instead. Conversely, Ho:YAG's average power is about 100 W and its presumable peak power is around 10-15 kW. With such an outburst of energy, each pulse of Ho:YAG creates a large vapor bubble which ruptures the tissue. This may be a possible reason for increased irritative symptoms in early postoperative period after HoLEP comparing to ThuFLEP. But all in all, the probable causes for such postoperative symptoms remain unclear so far, despite the fact that absence of irritation and incontinence is ought to be one quality marker of "Pentafecta". According to the idea of high-power impact, probably, decreasing of HoLEP power will mitigate these problems. On the one hand, low-power HoLEP is feasible, safe and effective modality for symptomatic BPO. However, the results remain controversial and there is lack of LP-HoLEP application data nowadays. May be, with another option, for instance OSP or monopolar enucleation, it is possible to solve the issues. But the discussion of the past years demonstrates that the presence of early SUI is not only a problem of EEP, but also underreported in other approaches in relieving BPO secondary to BPH.
OBJECTIVE: Predictors of arthritis development in patients with anti-citrullinated protein antibodies (ACPAs) and musculoskeletal symptoms are needed for risk stratification and to improve clinical outcomes. The aim of this study was to assess the relationship between serum protein electrophoresis (SPE) constituents and the development of clinical arthritis in ACPA-positive patients with musculoskeletal pain.
METHOD: We prospectively followed 82 ACPA-positive patients with musculoskeletal pain but no baseline arthritis during a median of 72 months (interquartile range 57-81 months). The primary outcome was arthritis development, as judged by clinical examination. SPE constituents were evaluated in baseline sera by immunoturbidimetric methods. Serum levels of the analysed proteins (albumin, orosomucoid, α1-anti-trypsin, haptoglobin, and immunoglobulins IgA, IgG, and IgM) were related to arthritis development by Cox regression analyses.
RESULTS: During the follow-up period, 39/82 patients (48%) progressed to arthritis. Median baseline levels of orosomucoid and α1-anti-trypsin were higher in patients who developed arthritis than in those who did not (p = 0.04), while median albumin levels were significantly lower (p = 0.03). Immunoglobulin levels did not differ between the groups. Univariable analysis demonstrated a significantly increased risk of arthritis with elevated baseline haptoglobin [hazard ratio (HR) 2.53, 95% confidence interval (CI) 1.32-4.85, p = 0.005] and orosomucoid levels (HR 2.63, 95% CI 1.09-6.31, p = 0.03). However, neither remained significant in multivariable analysis adjusting for elevated C-reactive protein (CRP) levels.
CONCLUSION: SPE does not add prognostic value for arthritis development in ACPA-positive patients with musculoskeletal pain.
One of the most important methods in the treatment of LBP in recent years is manual therapy; manipulation, mobilisation and soft tissue techniques. With the manual techniques applied to the spine, the position and placement of the anatomical structures are changed and the tight and tense tissues are loosened. It has been observed that Mulligan techniques can correct the faults that cause pain in the spine and that the structures that cause pain return to their normal functions when released. In the literature, it has recently been observed that the number of studies examining manual therapy and Mulligan Concept methods has increased. Studies examining the effect of SNAG method on the lumbar region (12) and the effect of mobilisation and taping on chronic low back pain were found. However, no study was found in which SNAG and NAGS applications were applied on obese patients diagnosed with mechanical low back pain. Therefore, in this study, SNAG and NAGS in obese patients with LBP to investigate the effectiveness of the practices
The present invention discloses a kind of spleen and kidney invigorating preparation and its preparation process and inspection method. The spleen and kidney invigorating preparation may be tablet or dripping pill and consists of dry extract powder, starch, calcium bicarbonate, carboxymethyl starch sodium and magnesium stearate. The tablet is prepared through the steps of extracting dry extract powder and preparing the spleen and kidney invigorating tablet. The dripping pill is prepared through the steps of extracting dry extract powder, forming pill and inspection. The spleen and kidney invigorating preparation has the functions of warming and invigorating kidney Yang, invigorating essence and blood, replenishing Qi, invigorating spleen, etc. and possesses the advantages of high stability, masked bitter taste, etc.
Methods of modulating peroxisome proliferator-activated receptor a (PPAR.alpha.) activity in a cell in a subject In need thereof are provided. The methods include administering an effective amount of a PPAR.alpha. ligand to the subject where the PPAR.alpha. ligand is selected from 3-hydroxy-2,2-dimethyl butyrate (HMB), hexadecananamide (HEX) and 9-octadecenamide (OCT), Methods of treating dementia, neurodegenerative disorders, lysosomal storage diseases and body weight disorders in a subject in need thereof are provided. The methods include administering an effective amount of a PPAR.alpha. ligand to the subject.
Un-interesterified blend of palm kernal and plam stearin. 50g fat.
<P>PROBLEM TO BE SOLVED: To provide a new useful pharmaceutical preparation or food capable of regulating immune balance.  <P>SOLUTION: The pharmaceutical preparation for regulating the immune balance comprising (B) at least one kind selected from lactulose or xylooligosaccharides in an amount of 1-20 pts.wt. based on (A) 1 pt.wt. of dead microbial cells of a lactic acid bacterium and containing 200,000,000,000 to 10,000,000,000,000 dead microbial cells of the lactic acid bacterium as a daily dose is provided. Furthermore, the food comprising (B) at least one kind selected from lactulose or xylooligosaccharides in an amount of 1-20 pts.wt. based on (A) 1 pt.wt. of the dead microbial cells of the lactic acid bacterium and containing 200,000,000,000 to 10,000,000,000,000 dead microbial cells of the lactic acid bacterium as the daily dose and having an indication that the food is used for regulating the immune balance is provided.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Dissection of human body donors is a common component of anatomy curricula, as it provides opportunities for tactile and intellectual engagement unmatched otherwise. Additionally, interaction with human body donors contributes to the "hidden curriculum" of allowing students to begin to ethically practice patient care with empathy, respect, and compassion. With this, there have been various proposed guidelines for the ethical treatment of human body donors, with most focusing on student reflections and a final ceremony for honoring the donors, but there are numerous other ways throughout the course to incorporate ethical values and to guide students to consider the humanity of the donor. This article proposes that institutions consider the incorporation of five easily implemented formalized ethical themes for working with human body donations into daily practices: (1) reflect the donor as possessing human dignity, (2) recognize the donor's role of the "First Patient" or "Silent Teacher," (3) honor the gift of human body donation, (4) recognize the decedent's family, and (5) consider inclusivity in memorialization practices. Multiple recommendations for integrating these five themes throughout the course are provided. The incorporation of these five core themes can assist in alleviating the psychological stress that some students struggle with in dissection courses, foster the feelings and attributes that comprise the hidden curriculum and are the desired characteristics of a caring medical provider, and discourage misuse and mistreatment of donors.